

1 Dopamine-gated memory selection during slow wave sleep

2

3 Hanna Isotalus 1, 2 *

4 -- hanna.isotalus@bristol.ac.uk

5 Will J Carr 1

6 -- wc17397@bristol.ac.uk

7 George G Averill 1

8 -- george.g.averill@gmail.com

9 Oliver Radtke 6

10 -- Oliver.Radtke@hhu.de

11 James Selwood 1, 3

12 -- james.selwood@bristol.ac.uk

13 Rachel Williams 1

14 -- Rachel.Williams@nbt.nhs.uk

15 Elizabeth Ford 1

16 -- b-ford@outlook.com

17 Liz McCullagh 7

18 -- liz.McCullagh@UHBristol.nhs.uk

19 James McErlane 1

20 -- james.mcerlane1@gmail.com

21 Cian O'Donnell 8

22 -- cian.odonnell@bristol.ac.uk

23 Claire Durant 4

24 -- Claire.Durant@bristol.ac.uk

25 Ullrich Bartsch 5

26 -- Ullrich.Bartsch@bristol.ac.uk

27 Matt W Jones 5

28 -- Matt.Jones@bristol.ac.uk

29 Carlos Muñoz Neira 1

30 -- carlos.munoz@bristol.ac.uk

31 Alfie R Wearn 1

32 -- alfie.wearn@bristol.ac.uk

33 John P Grogan 1,9

34 -- john.grogan@bristol.ac.uk

35 Elizabeth J Coulthard 1, 3 *

36 -- Elizabeth.Coulthard@bristol.ac.uk

37

38 *Corresponding authors

39 1 Clinical Neurosciences, Translational Health Sciences, Bristol Medical School, University of

40 Bristol, Bristol

41 2 Digital Health, Faculty of Engineering, University of Bristol, Bristol

42 3 Southmead Hospital, North Bristol NHS Trust, Bristol

43 4 Experimental Psychology, University of Bristol, Bristol

- 44 5 School of Physiology, Pharmacology and Neuroscience, University of Bristol
- 45 6 Department of Neurology, Centre for Movement Disorders and Neuromodulation, Medical
46 Faculty, Heinrich-Heine-University, Düsseldorf.
- 47 7 Production Pharmacy, University Hospital Bristol Pharmacy, University Hospitals Bristol NHS
48 Trust
- 49 8 School of Computer Science, Electrical and Electronic Engineering, and Engineering
50 Mathematics, University of Bristol, Bristol
- 51 9 Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford

52 The human brain selectively stores knowledge of the world to optimise future behaviour,
53 automatically rehearsing, contextualising or discarding information to create a robust record of
54 experiences. Storage or forgetting evolves over time, particularly during sleep. We sought to test
55 how dopamine shaped long term memory formation before and during sleep. We administered
56 dopamine (L-DOPA tablet) during learning, re-learning, consolidation or retrieval of word lists
57 in two independent double-blind randomised placebo-controlled cross-over studies of healthy
58 older adults (study 1 n = 35, study 2 n = 32). During consolidation, nocturnal dopamine
59 accelerated forgetting for words presented once, but did not affect words presented twice from
60 forgetting. Overnight dopamine increased total slow wave sleep duration by approximately 11%.
61 The effect of dopamine on memory correlated with increased spindle amplitude, which was
62 maximised near slow oscillation peaks, suggesting dopamine-dependent memory processing
63 modulates spindles dependent on slow-oscillation phase. Pharmaceutical modification of slow
64 wave sleep holds great promise for improving old age – potential benefits could include
65 cognitive enhancement and Alzheimer’s prevention.

66 Introduction

67 The brain selectively extracts and stores important details of our daily lives, while demoting
68 irrelevant information - you have probably forgotten where you parked your car while shopping
69 last week, but you will remember your parking slot in an airport carpark after a week's holiday.
70 Recent theories suggest that when memories are encoded, they form traces, known as engrams
71 ^{1,2}. Depending on context and relevance, engrams can be integrated within memory networks for
72 the long term, or forgotten through a set of processes that start immediately and progress during
73 wake and sleep ³⁻⁵.

74

75 During memory encoding and consolidation, engrams of important information can be
76 prioritised for storage, based either on previous knowledge, repeated exposure, or other
77 associations, such as financial or emotional reward or cost ^{6,7}. Contextual information
78 encountered at a later time-point can retroactively prioritise previous memories for storage ^{8,9}. At
79 a molecular level, synaptic tagging of engrams and protein synthesis increase the likelihood that a
80 memory undergoes synaptic consolidation ¹⁰. This synaptic strengthening usually occurs within
81 hours of encountering information ¹¹.

82

83 Thereafter, newly acquired memories are selected for long-term storage by spontaneous
84 repetition¹²; sleep affords an optimal neurophysiological state during which to enact this selection
85 process¹³. Patterns of activation within hippocampal neuronal assemblies at encoding are
86 selectively replayed during sharp wave ripples which are, in turn, temporally coupled to sleep
87 spindles, prominent during Non-REM (slow wave) sleep ¹⁴⁻¹⁸. The likelihood of replay during
88 ripples is increased for salient information ¹⁹, and disrupting these replay events has a detrimental
89 effect on memory ^{20,21}. Sleep appears to provide an optimal timeframe during which memories
90 are selected for long-term maintenance.

91

92 Sleep spindles provide an accessible electrophysiological metric, measurable in scalp EEG and
93 known to be coordinated with sharp wave ripples, that relates to systems consolidation of
94 memory during sleep. The neuroanatomical substrate of spindles includes hippocampo-thalamo-
95 cortical connections dependent on several neurotransmitters, interacting with ventral striatal and
96 midbrain dopaminergic regions ²². In turn, spindles are coupled to slow oscillations. However,
97 the roles these neurotransmitters play in these processes are not well understood.

98

99 Dopamine is released from midbrain neurons that connect the brain's reward and memory
100 systems, and modulate synaptic connections and memory longevity ²³. Dopamine release from
101 two midbrain areas - locus coeruleus and ventral tegmental area – directly projecting to the
102 hippocampus, is thought to selectively bias long term memory storage, perhaps through
103 reinforcement of synaptic tagging ^{11,12,22}.

104

105 Consistent with this model of systems memory consolidation, exogenous dopamine
106 administration can modulate memory persistence ²⁴⁻²⁷. In humans with dopamine depletion due
107 to Parkinson's disease, memory consolidation improves with overnight administration of L-
108 DOPA (Levodopa – which increases dopamine concentrations in the brain), but the timing of
109 the dopamine manipulation relative to learning critically determines its effects on memory ^{25,28}.

110

111 While dopamine may directly act during sleep *per se* ²⁹, dopaminergic modulation of sleep-
112 dependent memories may also reflect reinforcement and tagging (through triggering protein
113 synthesis) of important information during wakeful learning and consolidation ³⁰, prioritising
114 them for later replay during sleep ^{22,31,32}.

115

116 There is also evidence that neurons releasing dopamine may modulate forgetting. For instance,
117 *Drosophila* models point to dual effects of dopamine: it enhances encoding of new information
118 at the cost of triggering forgetting of competing information^{33,34}. This dopamine-induced
119 strategic forgetting is selective to weakly encoded memories – presumably, an automatic strategy
120 for ensuring retention of more behaviourally relevant information.

121

122 Together, these findings point to dual effects of dopamine in *selecting* memories for long term
123 storage. While dopamine strengthens important engrams, it can also actively promote forgetting
124 of weak information. The strengthening may be either at the stage of sleep through enhancement
125 of sleep replay, or during wake favouring long-term potentiation of tagged synapses, inducing
126 subsequent boosted replay during sleep.

127

128 Here we tested the hypothesis that dopamine biases human memory storage to maximise
129 retention of strong memory traces by increasing consolidation of words encoded twice whilst
130 accelerating forgetting for words only exposed to participants once. We predicted the primary
131 effects of dopamine during long-term memory evolution would be mediated through modulation
132 of slow wave sleep.

133

134 We report two double-blind randomised within-subjects placebo-controlled trials. In the first
135 study, we show that single doses of dopamine medication (L-DOPA) given after learning and
136 active during nocturnal sleep accelerate forgetting of non-repeated information. Investigation of
137 sleep characteristics revealed that spindle amplitude during slow wave sleep increases on L-
138 DOPA, compared to placebo. The magnitude of this increase correlates with the behavioural

139 effect of dopamine on memory selection. In the second placebo-controlled drug study we did
140 not find any effects of L-DOPA on encoding or retrieval of episodic memory, further suggesting
141 that the effects of L-DOPA in the first (and main) experiment were enacted during repetition,
142 consolidation and/or sleep.

143

144 Results

145 To study the relationships between dopamine, sleep and forgetting, we carefully timed
146 administration of L-DOPA to increase dopamine concentration within the brains of healthy
147 older adults across two placebo-controlled double-blind randomised crossover experiments. The
148 overarching structure of the two experiments enabled targeting of L-DOPA to different memory
149 processes – in Experiment 1 (**Fig 1a**), we explored the effects of dopamine on memory
150 consolidation by administering L-DOPA after learning, to be active after initial learning and
151 during nocturnal sleep³⁵. In Experiment 2, L-DOPA was only active during memory retrieval
152 (testing) or encoding (learning) and not during sleep.




Fig 1: Experiment 1 Study procedure

- a.** In this placebo-controlled randomised crossover trial, healthy elderly volunteers completed two overnight visits. In the evening, they learnt 4 lists of 20 words (Lists i, ii, iii and iv) 1h *before* receiving 200mg L-DOPA CR or placebo. 1.5h *after* dosing memory was tested on a quarter of the words (List i) in order to promote stronger encoding by re-exposure. Full nights of polysomnography were recorded on both nights. Memory for each item was tested after a 1, 3, or 5-day delay. Apart from treatment (L-DOPA or placebo) the nights were identical.
- b.** During learning, participants saw 80 words, one at a time, which were later separated into four lists for testing (i, ii, iii, iv – 20 words each); the words were shown in a random, interleaved, order during learning. 1.5 hours later, they were re-exposed to List i during a recognition test. The following day, memory for Lists i and ii were tested (random, interleaved), while lists iii and iv were tested 3 and 5 days later over the phone. Each test was performed using a recognition test with a unique set of distractor words. The testing procedure was fully explained to participants before learning.

153

154 In the first within-subjects study, 35 healthy elderly volunteers (age = 68.9 ± 3.5 years; 22

155 Female) completed two overnight study visits (**Fig 1a**) which were identical except for treatment

156 allocation.

157 On the visits, we administered controlled release L-DOPA (CR; co-beneldopa 200/50mg) or

158 placebo *after* participants had learnt information (four 20-word lists, Lists i, ii, iii and iv , **Fig 1b**).

159 The words were presented one at a time, in a random and interleaved order. Participants were re-

160 exposed to a quarter of the items (List *i*) shortly after L-DOPA (or placebo) administration
161 through a recognition memory test – this manipulation was performed to strengthen the
162 memory for each List *i* word. Memory for the re-exposed items (List *i* – strengthened memory)
163 was tested the following day together with a matched number of items that had not been re-
164 exposed (List *ii* – weak memory; along with novel foils in a random, interleaved order). Memory
165 for the remainder of the items was probed 3 or 5 days after learning (Lists *iii* and *iv*). The
166 participants knew some words would be tested both in the evening and in the morning, and the
167 remainder of the words would only be tested once.

168

169 We used d' (D-prime) as a measure of recognition accuracy for each list. d' is a sensitivity index
170 that takes into account both the accurately detected signal (hits) and inaccurately identified noise
171 (false alarms)³⁶. In other words, d' captures not just correctly identified “old” words during the
172 recognition test, but it also accounts for incorrect judgements of “new” items as “old”. d' is the
173 difference between the Z-transformed rates of correct hit responses and incorrect false alarms. A
174 higher d' therefore indicates better ability at performing the task, while a d' of 0 indicates chance
175 level performance.

176

177 Initial learning occurred before L-DOPA (/ placebo), whereas memory re-exposure and a full
178 night of sleep occurred after L-DOPA (/ placebo). Therefore, we were able to isolate the effects
179 of dopamine on re-exposure, consolidation and sleep-dependent processing from its effects on
180 initial encoding. Items presented only once (Lists *ii*, *iii*, *iv*) were expected to have induced weaker
181 memory traces than the re-exposed items (List *i*).

182

183 L-DOPA accelerates forgetting during sleep

184 L-DOPA given after learning accelerated forgetting of items presented only once when memory
185 was tested the next day (List *ii*) but not at greater delays (Lists *iii*, *iv*, **Fig 2a**). First, we performed
186 pairwise comparisons between the L-DOPA and placebo conditions for each single-exposure
187 list. These comparisons demonstrated that d' was reduced on L-DOPA ($d'_{\text{List } ii} = 1.249 \pm 0.59$)
188 compared to placebo ($d'_{\text{List } ii} = 1.544, \pm 0.65$) at Day 1 (paired $t(34) = -3.333, p = 0.002, \text{BF}_{10} =$
189 16.6). By Day 3 there was no difference ($d'_{\text{List } iii}$: L-DOPA = 0.86 ± 0.46 ; placebo = 0.82 ± 0.63 ;
190 Wilcoxon's $Z = 338, p = 0.313, \text{BF}_{01} = 5.2$; $d'_{\text{List } iv}$: L-DOPA = 0.58 ± 0.58 ; placebo = $0.59 \pm$
191 0.55 ; $t(34) = -0.02, p = 0.982, \text{BF}_{01} = 5.4$). Together these findings show that L-DOPA
192 accelerates the speed of forgetting for information over 1 night, but this information would be
193 lost in the longer term even without L-DOPA (**Fig 2a**). This suggests that dopamine may play
194 an important part in either selecting memories for storage or initiating forgetting.

195

196 Body weight is known to influence the cumulative dose and pharmacokinetic properties of L-
197 DOPA in humans³⁷, as well as L-DOPAs effect on memory in humans²⁶. We used a mixed
198 linear model to investigate the effect of dose (based on body weight) within both treatment
199 conditions (placebo vs L-DOPA). A model with weight-adjusted dose (mg/kg), delay from
200 learning (days) and the interaction term (delay * dose) as fixed effects and participants as random
201 effects revealed a main effect of delay ($n = 35, t(33.7) = -9.142, p < 0.001, \text{Supplementary Table 1}$),
202 no overall effect of dose ($t(20.3) = -1.36, p = 0.188$) and a delay * dose interaction ($t(98.2) =$
203 $2.33, p = 0.022$). Next, we performed a series of post-hoc correlational analyses to determine
204 which effects were driving this interaction.

205

206 The degree of forgetting correlated with L-DOPA dose (Spearman's $\rho = -0.56, p < 0.001$) but
207 not with placebo (**Fig 2b** – Spearman's $\rho = -0.23, p = 0.18$). The degree of forgetting did not
208 correlate with L-DOPA dose ($p > 0.36$) on days 3 or 5 in either condition. The lack of

209 correlation in the placebo arm suggests that these effects were not driven by bodyweight. The
210 delay*dose interaction was therefore driven by L-DOPA affecting memory for List *ii* on Day 1
211 but not at subsequent delays. This suggests that L-DOPA accelerates initial forgetting in a dose-
212 dependent manner, but it does not influence memory for items that would be retained 3 or 5
213 days later.
214




Fig 2: Nocturnal dopamine dose-dependently modulates memory

- a. Higher d' at Day 1 on placebo (green) compared with L-DOPA (red) shows that overnight L-DOPA increased forgetting when memory was tested next day (List *ii*) but not when memory was tested 3 or 5 days later (Lists *iii* and *iv* respectively) compared to placebo. Therefore, L-DOPA during sleep accelerates forgetting of weakly encoded information that is naturally forgotten by day 3. Note that L-DOPA was no longer active during memory tests. Bars in box plot present medians and quartiles.

-
- b. Higher L-DOPA dose during consolidation was correlated with poorer Day 1 recall of List *ii* d' (Spearman's $\rho = -.056$, $p < 0.001$, red) but no such relationship was found on the placebo night ($\rho = -0.23$, $p = 0.180$, green). Notably, the difference between these two relationships was also different (Pearson's r -to- z transform $z = -2.634$, $p = 0.008$). Lines of best fit are presented for illustration purposes.
- c. L-DOPA increased the relative benefit of re-exposed compared to other items (List *i* d' minus List *ii* d') with medians (horizontal line). This relative benefit was larger when L-DOPA ($d'_{\text{List } i - ii} = 0.953 \pm 0.67$) compared to placebo ($d'_{\text{List } i - ii} = 0.643 \pm 0.56$) was given ($t(34) = 2.48$, $p = 0.018$, $BF_{10} = 2.6$). This difference was driven both by an increase in List *i* d' and decrease in List *ii* d' on L-DOPA (although the former was not significant, $p > 0.05$).
-

215

216 L-DOPA rescues stronger memory traces from forgetting

217 Next, we investigated whether dopamine modulates how re-exposure affects memory. Strong

218 memory traces (re-exposed items - List *i*) were better retained (more 'hits') than others (List *ii*)

219 both following L-DOPA (**Hits** $_{\text{List } i} = 18.1 \pm 3.3$; **Hits** $_{\text{List } ii} = 13.8 \pm 3.3$; $t(34) = 8.49$, $p < 0.001$)

220 and following placebo (**Hits** $_{\text{List } i} = 15.0 \pm 3.0$; **Hits** $_{\text{List } ii} = 18.0 \pm 2.4$; $t(34) = 7.18$, $p < 0.001$).

221 While L-DOPA accelerated baseline forgetting for weaker items ($d'_{\text{List } ii} = 1.25 \pm 0.59$) compared

222 to placebo ($d'_{\text{List } ii} = 1.54 \pm 0.11$, $t(34) = -3.333$, $p = 0.002$, $BF_{01} = 0.1$, *Supplementary Figure 1*), re-

223 exposed List *i* items were rescued from this effect ($d'_{\text{List } i} = 2.20 \pm 0.78$; placebo $d'_{\text{List } i} = 2.19 \pm$

224 0.77 ; $t(34) = 0.134$, $p = 0.894$, $BF_{10} = 5.5$, **Fig 2c**, *Supplementary Table 2*). Therefore, L-DOPA

225 selectively biased memory retention away from non-repeated items with the result that more

226 repeated compared to non-repeated items were remembered at day 1.

227

228 To quantify the relative effect of dopamine on repeated compared to non-repeated items, we

229 used the paired difference between the strongly and weakly encoded lists (i.e. d' for List *i* minus

230 d' for List *ii*) from the Day 1 recognition test. This relative benefit was larger after L-DOPA (d'

231 $_{\text{List } i - ii} = 0.953 \pm 0.67$) compared to placebo ($d'_{\text{List } i - ii} = 0.643 \pm 0.56$) administration ($t(34) = 2.48$,

232 $p = 0.018$, $BF_{10} = 2.6$, **Fig 2c**).

233

234 To reiterate, L-DOPA differentially modulated strong and weak memory traces, augmenting
235 differences between them. Furthermore, we performed two post-hoc analyses that showed that
236 the treatment had no effect on the false alarm rate ($t(34) = 0.527$, $p = 0.601$, $BF_{01} = 4.8$). Rather,
237 L-DOPA reduced the hit rate (List *ii* – $t(34) = -2.89$, $p = 0.007$, $BF_{10} = 6.0$) – the hits rather than
238 the false alarms drive all the effects of L-DOPA on d' we identified. This implies that effects of
239 dopamine are related to engram strength rather than modulation of noise that generates false
240 responses.

241

242 It is important to note that there was no difference in performance during the evening re-
243 exposure tests between placebo and L-DOPA conditions (Day 0 List *i* paired $t(34) = .83$, $p =$
244 0.412 , $BF_{01} = 4.0$). Note that the Bayes Factor (BF_{01}) suggested that these results were 4 times
245 more likely to have been recorded under the null than the alternative distribution. Therefore,
246 dopamine did not affect memory performance before sleep – the effects we report here only
247 manifest *after* a night of sleep.

248

249 Together, these findings provide strong evidence that dopamine biases selection of memories for
250 long term storage by accelerating forgetting of weakly-encoded information with the net effect of
251 promoting repeated items for storage. Next, we explored polysomnography measures for
252 potential neurophysiological mechanisms underlying dopamine's effects on memory.

253

254 L-DOPA prolongs slow wave sleep

255 Nocturnal L-DOPA increased time spent in slow wave sleep (stage N3) by ~10.6% (**Fig 3a**) but
256 did not markedly affect the time in other sleep stages or total sleep time (*Supplementary Table 3*).
257 As most slow wave sleep occurs in the first 4 hours of sleep and the absorption profile of L-

258 DOPA controlled release strongly predicts that dopamine would be increased in the first half of
259 the night³⁵, we expected that any increase in slow wave sleep would be in the first half of the
260 night. As predicted, the observed increase in slow wave sleep occurred only during the first half
261 of the night (as defined by lights-off and lights-on times) on L-DOPA (90.2 ± 34.1 min)
262 compared to placebo (76.8 ± 30.3 min, ($n = 31$, $t(30) = -3.07$, $p = 0.005$, $BF_{10} = 8.7$ for missing
263 data see *Supplementary Table 4*). L-DOPA did not have significant effects on slow wave sleep
264 duration during the second half of the night ($t(30) = -0.387$, $p = 0.703$, $BF_{01} = 4.9$).

265

266 Next, we explored if L-DOPA's effect on the total slow wave sleep duration was associated with
267 its effects on memory. Overall slow wave sleep duration was strongly correlated with d' for the
268 repeated items (List *i*) on placebo (Spearman's $\rho = 0.450$, $p = 0.009$). This effect did not occur
269 for List *ii* (non-repeated items) and it disappeared after participants took L-DOPA (List *ii*
270 Spearman's $\rho = -0.043$, $p = 0.810$, **Fig 3b**). This suggests that slow wave sleep duration is
271 important for consolidation of stronger memory traces, and that, while L-DOPA increases slow
272 wave sleep duration, this alone does not explain how dopamine rescues strong memory traces
273 from forgetting.

274

275 Next, we asked what mechanism underlies the quicker forgetting of weaker compared to
276 stronger memory traces. Therefore, we performed several exploratory analyses to investigate the
277 relationship between behavioural effects of dopamine and more fine-grained sleep
278 characteristics.




Fig 3: L-DOPA and slow wave sleep duration

- Paired differences in slow wave sleep duration shows that most volunteers (dots above zero) had increased slow wave sleep on L-DOPA compared to placebo. The duration was increased by an average of $\sim 10.6\%$ on L-DOPA compared to placebo ($t(31) = 2.702$, $p = 0.011$, $BF_{10} = 4.0$). This effect remained after false discovery rate correction accounting for each sleep stage (corrected $p = 0.044$).
- Longer slow wave sleep duration was correlated with better memory for strongly encoded information on placebo (Spearman's $\rho = 0.45$, $p = 0.009$, green), but after L-DOPA was given this effect disappeared ($\rho = 0.043$, $p = 0.810$, red). The difference between the two relationships was significant (Pearson's r -to- $z = -1.99$, $p = 0.046$), and the effect on placebo remained after correcting for false discovery rate (corrected $p = 0.036$). This strongly suggests that L-DOPA does not increase the relative effect of re-exposure by merely increasing sleep. Lines of best fit are presented for illustration.

279

280 L-DOPA increases spindle amplitude

281 Spindles are a prominent feature of Stage 2 – the period immediately before Stage 3 slow wave
282 sleep – they persist during slow wave sleep, and are associated with memory retention^{38,39}.

283

284 L-DOPA induced a small but significant increase in average spindle amplitude – this increase
285 was manifest in 25 out of 31 participants with spindle data available (**Fig 4a**, *Supplementary Table*
286 *5*). Exploratory analyses revealed that this change was not correlated with the weight adjusted
287 dose (Pearson's $r = -0.139$, $p = 0.456$), nor did we find any correlations between spindle
288 amplitude and the relative benefit of re-exposure (i.e. d' difference between Lists i and ii) on

289 either L-DOPA (Spearman's $\rho = 0.047$, $p = 0.801$) or Placebo (Spearman's $\rho = -0.040$, $p =$
290 0.833). However, greater spindle amplitude following L-DOPA, compared to placebo, was
291 associated with a larger memory benefit for strong rather than weak memory traces (difference in
292 d' between Lists i and ii , **Fig 4b**).

293

294 In other words, the rescue effect of L-DOPA observed behaviourally correlated with a change in
295 spindle amplitude on L-DOPA. This effect was specific to the L-DOPA-mediated *change* in
296 relative benefit of re-exposure on memory and spindle amplitude. This effect was not present for
297 List i or ii alone (*Supplementary Table 6*).

298

299 L-DOPA affects spindles most at slow oscillations peaks

300 Temporal coupling between slow oscillations and spindles have been shown to predict memory
301 performance, and this coupling is impaired by aging⁴⁰. We explored whether L-DOPA's effects
302 on memory performance could be due to an alteration of the slow oscillation – spindle coupling.
303 First, we segmented those slow oscillations where spindles were present into 4 different phase
304 bins. Then, we calculated the effect of L-DOPA on spindle amplitude separately for each bin.

305

306 L-DOPA had a slow oscillation phase dependent effect on spindle amplitude, with a larger
307 increase around zero phase (**Fig 4c**). The peak change occurred in the $-\pi/4$ to $+\pi/4$ bin, the same
308 bin that showed the highest mean spindle amplitude for both L-DOPA and placebo conditions
309 (**Fig 4c, 4d**). L-DOPA therefore altered the neural dynamics that underlie the synchronised
310 relationship between slow oscillations and spindles. This may represent either a phase-specific
311 effect of dopamine on spindle amplitude during sleep, or a secondary effect on these dynamics
312 caused by a dopaminergic bias of early awake consolidation.

313

314 We found no behaviourally relevant associations between L-DOPA and other slow oscillation
315 characteristics (all p s > 0.49 , *Supplementary Tables 5*). Exploratory analyses revealed no differences
316 between L-DOPA and placebo on subjective sleep measures (St Mary's Hospital Sleep
317 Questionnaire ⁴¹ or Leeds Sleep Evaluation Questionnaire (*Supplementary Table 7*) ⁴².

318

319 Overall, we found that dopamine increases forgetting of weak memories but protects stronger
320 memories. The dopamine-driven prioritisation of memories correlates with sleep spindle
321 characteristics.




Fig 4: L-DOPA, memory and spindle amplitude

- Nocturnal L-DOPA increased spindle amplitude ($n = 31$, Wilcoxon's $z = 401$, $p = 0.002$, $BF_{10} = 3.6$) suggesting an effect of L-DOPA on regional coherence during slow wave spindles.
- The L-DOPA mediated increase in spindle amplitude was associated with the L-DOPA mediated increase in the relative benefit of re-exposure on d' (**Fig 2c**) (Spearman's $\rho = 0.438$, $p = 0.015$). Note that this relationship is non-linear, line is fitted in the figure for illustration.
- The dopamine-induced spindle amplitude increase is slow oscillation phase-dependent. Mean spindle amplitude change (normalised to baseline amplitude ($[\text{placebo} + \text{L-DOPA}]/2$)) is higher on L-DOPA around the zero phase of slow oscillations. We compared the effect of L-DOPA at the peak (zero phase) and trough (π phase) of the slow oscillation. The L-DOPA mediated spindle amplitude increase was larger in the 4 zero-centric bins compared to the 4 π -centric bins (outermost on either side) – (paired $t(30) = 2.12$, $p=0.043$, $BF_{10} = 1.3$). Yellow bars show the mean amplitude change with individual participants' spindle amplitude change overlaid. Spindle amplitude peaked in the $-\pi/4$ to $-\pi/8$ phase bin for both placebo and L-DOPA.
- Peak-locked grand average mean slow oscillation events (grey) superimposed with the peak-locked average of all spindle events (blue) that occurred during slow oscillations – averaged across both L-DOPA and placebo nights.

322 L-DOPA does not modulate memory at encoding or retrieval – Experiment 2

323 To investigate whether dopamine was affecting other stages of memory (encoding, retrieval), we
324 ran a different placebo-controlled experiment manipulating dopamine levels at each of those
325 stages.

326 A total of 35 elderly participants were given short-acting L-DOPA an hour before encoding and,
327 in a separate memory task, an hour before retrieval (*Supplementary Figure 3, 4*). In the encoding
328 tasks, recall was tested after 1, 3 and 5 days. We did not find an effect of L-DOPA on encoding
329 ($t(28) = -.352, p = .728, BF_{01} = 4.6$) or retrieval ($t(27) = -.393, p = .698, BF_{01} = 4.6$) with a 24-
330 hour delay between learning and test (*Supplementary Table 8*). Therefore, at the doses and timings
331 used here, dopamine appears to have a temporally and functionally specific effect biasing
332 memory towards important information after initial learning, during either re-exposure, sleep or
333 both.

334

335 Discussion

336 Here we show specific effects of nocturnal dopamine augmentation on weak compared to strong
337 memories. Dopamine accelerates forgetting for weakly encoded information during sleep – while
338 more strongly encoded information is relatively preserved – and increases duration of slow wave
339 sleep by 10.6%. The behavioural effect of dopamine on strongly versus weakly encoded
340 information is associated with a dopamine-driven increase in spindle amplitude during slow wave
341 sleep. This increase in spindle amplitude only occurs around the peak of slow oscillations.

342

343 Traditionally, forgetting is considered a passive process where information is “lost”. However,
344 newer animal models strongly support an active, more strategic, forgetting process mediated by

345 dopamine^{33,34,43,44}. Here we demonstrate an analogous *active* forgetting dopamine-dependent
346 mechanism in humans.

347

348 Dopamine enhanced active forgetting for information tested at a 1-day delay but not at later
349 timepoints. Therefore, dopamine may accelerate forgetting of low importance information that
350 would inevitably be lost over time allowing the prioritisation of effective consolidation of high
351 importance items. Such prioritisation may be further explained – through analogy with
352 drosophila experiments – by a second dopaminergic system that protects important information
353 from forgetting⁴³. Human behavioural evidence supports preferential consolidation of salient or
354 rewarded information during sleep^{13,45,46} and we tie this more closely to dopaminergic
355 modulation. However, we did not see a dopamine-driven enhancement in consolidation of
356 strongly encoded information.

357

358 There is clear evidence that memory processes before sleep can alter slow wave sleep
359 characteristics, particularly in the early part of the night⁴⁷. We administered dopamine while
360 participants were awake, and they fell asleep around 2.5 hours later, thus it is possible that at least
361 a portion of the dopaminergic enhancement of forgetting occurred during wake, before sleep.
362 We were not recording electroencephalography during wake, so cannot rule this out, but did
363 observe effects of L-DOPA on sleep architecture, whereby it increased slow wave sleep duration
364 in the first but not in the second half of the night, when L-DOPA was most available, suggesting
365 sleep-dependent effects.

366

367 The observed increase in slow wave sleep duration by L-DOPA may be specific to older people.
368 Models in non-aged animals suggest that D2 receptors promote wakefulness⁴⁸ and dopamine

369 levels are generally higher during wake than sleep in animals ⁴⁹. In young healthy adults, direct
370 administration of a dopamine *antagonist* during slow wave sleep actually increases the duration of
371 slow waves sleep ⁵⁰. It has been noted before that the wake-promoting effects of dopamine in
372 the young contradict the sleepiness that is a recognised side effect of L-DOPA in patients with
373 Parkinson's disease ⁵¹. Given the loss of dopaminergic neurons that occurs with age ⁵²⁻⁵⁴, the
374 effects of L-DOPA on memory and sleep could be age-dependent.

375

376 While spindles are well linked to memory and neurodegeneration ⁵⁵, this study directly links
377 dopamine with behavioural relevance of spindles. Spindle amplitude is shaped by the interplay
378 between the thalamus and the cortex ⁵⁶, and increased amplitude reflects a more coherent and
379 wider topographical expression of spindle-related activity ^{57,58}. Spindle amplitude has also been
380 associated with enhanced memory retention during a motivated forgetting task ⁵⁹ and during a
381 tagging paradigm ⁶⁰ suggesting that it may be associated with selecting memories for later
382 retention. Here, greater spindle amplitude was correlated with a larger relative benefit of
383 dopamine on retention of strongly, as opposed to weakly, encoded information.

384

385 L-DOPA mainly increased spindle amplitude just before the peak of slow oscillations, which
386 occurred despite no change in slow-oscillation amplitude. Spindles, particularly when nested in
387 slow oscillation peaks, are hallmarks of sleep-dependent memory consolidation ⁶¹. Age-related
388 uncoupling of spindles from peak of slow oscillations increases overnight forgetting ⁴⁰. We
389 interpret dopaminergic increase in spindles synchronised to near zero phase of slow oscillation as
390 enhancement of physiological spindle activity to modulate memory consolidation.

391

392 There are two possible explanations for our finding – (1) dopamine either directly enhances
393 spindle amplitude which in turn enhances the way in which memory is biased in favour of salient
394 information (2) or dopamine during memory re-exposure before sleep results in stronger
395 behavioural tags that in turn alter subsequent spindle amplitude to reflect the changes in the
396 memory engram that took place during tagging. These effects are not mutually exclusive, and
397 indeed could be interacting. Future experiments separating the effects of sleep consolidation
398 from re-exposure benefit are necessary to disentangle this.

399

400 We suggest that two simultaneous processes may be at play (**Fig 5**). First, during learning a
401 portion of information is “tagged” as important⁶², and dopamine enhances this process by
402 creating a stronger tag^{63,64}. Second, during subsequent sleep, dopamine increases forgetting for
403 the less important, non-tagged items while the tag shields the important (or re-exposed)
404 information from forgetting^{65,66}. This theory has been proposed before, and the current study
405 adds to it by implicating (dopamine-mediated) crosstalk between the thalamus and the cortex
406 during spindles as a potential mechanism for the later effects.

407

408 Given the individual differences and age-related changes in sleep architecture and dopaminergic
409 systems, here we used a crossover design to allow within-subject comparisons between L-DOPA
410 and placebo. We also tested older people exclusively for two reasons. Critically, memory loss is a
411 prominent problem in old age and our eventual goal is to improve quality of life through
412 cognitive enhancement, justifying the use of a target population of interest to future trials.
413 Second, there is drop-out of dopaminergic neurons that comes with old age⁵²⁻⁵⁴ which has been
414 shown to affect the impact of taking dopaminergic medications on cognition⁶⁷. Therefore, age-
415 related lowered dopaminergic level would lead to a greater difference between drug and placebo
416 conditions.

417

418 Ageing decreases the duration of slow wave sleep, and the number and amplitude of spindles ⁶⁸,
419 with some reporting nearly a 50% reduction in spindle amplitude with advanced age ⁶⁹.
420 Furthermore, slow wave sleep may be affected early in Alzheimer's Disease ⁷⁰. Interrupting slow
421 wave sleep is proposed to hinder clearance of amyloid from the brain and amyloid plaques are
422 one of the key pathological changes in Alzheimer's Disease ^{71,72}. L-DOPA is routinely prescribed
423 for Parkinson's disease with a good safety profile; however, the impacts of L-DOPA on sleep
424 have not been assessed in detail except in small studies of Parkinson's disease ⁷³⁻⁷⁵. Our finding
425 that L-DOPA may ameliorate age-dependent spindle loss with concomitant memory benefits
426 could be promising for treating age-related memory decline, or more severe memory deficits
427 found in Alzheimer's dementia. Perhaps more excitingly, our current findings may have
428 implications for prevention of Alzheimer's disease. Through increasing slow wave sleep duration
429 and spindle amplitude with nocturnal dopamine, we open up a new therapeutic avenue for
430 Alzheimer's disease prevention – repurposing L-DOPA to prevent Alzheimer's.

431

432 Together, our findings suggest that the repetition-benefit on memory is improved by dopamine
433 at the time of the repetition and during sleep-consolidation, which is mediated by increased slow
434 wave sleep duration and spindle amplitude. We propose that this dopamine-induced increase in
435 spindle amplitude reflects more synchronous cortical activity during spindles augmenting the
436 difference between strongly and weakly encoded engrams, biasing later retention towards
437 strongly-encoded engrams (**Fig 5**). These findings have potential clinical impact in enhancing
438 sleep and memory in old age, and in mild amnesic disease.




Fig 5: Dopamine modulates memory after learning by enhancing memory prioritisation and subsequent sleep processes.

A proportion of important information (yellow engram) is earmarked for retention by a neural “tag” during re-exposure (blue pin). Dopamine during re-exposure enhances this effect (red pins) at the expense of unpinned engrams (green). During sleep, weak engrams are preferentially forgotten to allow more consolidation of ear-marked information, leading to a more selective memory trace. Dopamine modulates these selective memory processes by enhancing synchronisation in cortical firing patterns during spindles, at the peak of slow oscillations. Together these two processes (enhanced prioritisation and synchronisation) bias subsequent memory. Important information (yellow dots) is much more likely to be remembered subsequently, and this effect is increased by dopamine.

439 **Method**

440 **Participants**

441 We recruited 70 elderly (65+ years) volunteers to complete the two studies reported here (n = 35

442 each study, see (*Supplementary Tables 4, 9, 10*) for demographic information and

443 inclusion/exclusion criteria). All aspects of this research adhered with the Declaration of

444 Helsinki and we had relevant ethical and regulatory (UK) approvals in place (Study 1 ISRCTN:
445 90897064).

446

447 **Design**

448 Study 1: In the first placebo-controlled double-blind randomised study, volunteers were initially
449 screened over the phone for common exclusions, and then invited for three in-house visits. On
450 the first visit they were fully screened for eligibility, and they practiced the memory task. They
451 were asked about their usual sleeping pattern so that the second and third visits could be
452 designed to follow each participants' usual sleep routines as much as possible. On the second
453 visit, volunteers arrived on site in the evening where they were re-consented and screened for
454 continued eligibility. For an outline of the evening see (**Fig 1a**, *Supplementary Figure 2*).

455

456 First, volunteers learnt a verbal memory task (**Fig 1b**, *Supplementary Figure 3*). Thirty minutes after
457 learning, they were given 200mg L-DOPA or placebo. An hour after dosing, a quarter of the
458 items (List *i*) were re-exposed by a recognition test where no feedback was given. The purpose
459 of this test was to create a stronger memory trace. An hour after the re-exposure (two hours after
460 L-DOPA was given), the volunteers went to bed. Each evening was designed based on each
461 participants' usual sleeping pattern: L-DOPA was administered 115 minutes prior to switching
462 the lights off for the night at their usual bedtime.

463

464 Volunteers slept on-site for a full night, and they were woken up at their usual wake-up time.
465 Around 1.5h after waking up, approximately 12h after dosing, volunteers' verbal memory was
466 tested again (Lists *i* and *ii*) before they left the study site. 2 and 4 days later (3 and 5 days after

467 learning) they were contacted over the phone for follow-up recognition memory tests (for Lists
468 *iii* and *iv*, respectively).

469

470 The second and third visits were identical except for treatment (L-DOPA / placebo) allocation.

471 Study 2: To test L-DOPA's effect on retrieval, participants learnt a word list on day -1 (relative
472 to dosing). 24 hours later, on Day 0, participants returned on site and received 10mg of Madopar
473 (anti-emetic) and 30 minutes later co-beneldopa (containing 150mg L-DOPA) or placebo
474 (vitamin C) – cross-over design with order-randomised placebo vs L-DOPA visits (*Supplementary*
475 *Figure 3, 4*).

476 An hour after dosing, to test L-DOPA's effect on retrieval, recognition memory of the words
477 learnt the previous day was tested. Next, to test L-DOPA's effect on encoding, participants
478 learnt another list of words on which their memory was assessed the following day (Day 1).
479 Therefore, for the first list L-DOPA was not active during encoding or nocturnal consolidation,
480 but it was active at retrieval. For the second list, L-DOPA was active during encoding and
481 shortly after, but not during nocturnal consolidation and retrieval.

482 This study obtained ethical approval from the University of Bristol Faculty of Medicine and
483 Dentistry Ethics Committee (REF: 12161).

484 **Treatment**

485 In the first placebo-controlled randomised double-blind study, each participant was dosed with
486 co-beneldopa controlled release (containing 200mg L-DOPA) was given in capsule form and
487 placebo (encapsulated inert powder, matched for appearance). Blinding and randomisation was
488 performed in blocks of 6 by author LM, Production Pharmacy, University Hospital Bristol
489 Pharmacy, University Hospitals Bristol NHS Trust. On the study nights, dose was given by an
490 on-site medic who was blind to treatment condition and played no role in collecting data. The

491 treatments were given at different visits. Both treatments were preceded by Motilium 10mg
492 (tablet) to alleviate possible nausea caused by L-DOPA. The medic stayed on site for 2.5h after
493 dosing the L-DOPA/placebo.

494 While the two experiments were designed to complement one another, for practical reasons
495 there were several important differences in study designs. First, the L-DOPA given in study 1
496 was long-acting and of higher dose (4-8 hours cf 1-4 hours and 200mg cf 150mg) to target
497 consolidation during sleep which is a longer process than encoding or retrieval. Second, the
498 controlled release L-DOPA in study 1 was given in capsule form, whilst in Study 2 we used
499 dispersible L-DOPA. For this reason, the placebo used in Study 1 was encapsulated inert
500 powder, whilst in Study 2 we used dispersible vitamin C. These differences and individual
501 differences in dopamine absorption and metabolism introduce unmeasurable differences
502 between the two experiments that need to be considered when interpreting differences between
503 them. Within each experiment we used placebo-controlled, randomised, crossover designs to
504 remove these confounds strengthening conclusions that can be drawn.

505

506 **Verbal memory test**

507 Study 1: volunteers learnt four lists (*i*, *ii*, *iii*, and *iv*) of 20 target words (total 80 targets) presented
508 on a computer screen one at a time, in a random, interleaved order (**Fig 1b**, *Supplementary Figure*
509 *2*). Each word was presented once for 3.6s during which the volunteers were asked to determine
510 if the items were alive or not to assist learning. They were instructed to remember as many of the
511 words as they could.

512

513 During test phases, volunteers were presented with a list of 40 (days 0, 3, and 5) or 80 words (day
514 1), half of which were targets (present at learning) and half of which were distractors (not

515 presented previously). They were asked to judge whether words were targets or not. On days 0,
516 1, 3, and 5 memory was tested for Lists *i*, *i* and *ii*, *iii*, and *iv* respectively. Therefore, List *i* was
517 tested twice: First in the evening while L-DOPA (/ placebo) was active in the system and then
518 again in the morning together with List *ii*. The re-exposed and novel (List *i* and List *ii*,
519 respectively) targets tested on day 1 were assessed to study L-DOPA's effect on behavioural
520 tagging of 'important' information. The rationale was that when a word is presented a second
521 time (during re-exposure), it will be deemed more important and will be preferentially
522 remembered. The distractors were unique at each test.

523

524 Study 2: The purpose of this study was to test L-DOPA's effects on retrieval and encoding. Two
525 separate memory tests were conducted (*Supplementary Figure 3, 4*).

526

527 *Retrieval:* During learning on D-1 (day before dosing) volunteers were presented with 48
528 complete nouns on a computer screen. They were instructed to read the words aloud and try to
529 memorise them for later. Each word was shown once for 5 seconds separated by a fixation cross
530 in the middle of the screen for 2 seconds and no responses to the words were made during
531 learning. There were no breaks in the learning block (total duration = 5mins 36secs).

532 Memory was tested using unique words 30 minutes (D-1, baseline) and 24 hours (D0) after
533 learning. The D0 test was given when L-DOPA was at its peak concentration (~ 1h following
534 dosing). In the test phases (D-1 and D0).

535

536 *Encoding:* D0 around 1.5 hours after dosing, after the test for the previous task had finished. At
537 learning, volunteers saw 96 complete nouns presented on the computer screen. Each word was
538 displayed for 5 seconds, followed by a fixation cross for 2 seconds. The words were first

539 presented in a random order in two blocks, and then again in another random order, again in
540 two blocks (n blocks = 4, n words per block = 48, n breaks =3, block duration = 5 minutes 36
541 seconds). Therefore, each word was shown twice to enhance learning.

542 Memory was prompted immediately after learning (D0), and 1, 3 and 5 days after learning (D1,
543 D3, D5). Each target was tested once. At each test, 24 unique targets and distractors were tested.
544 Test on D0 followed the same procedure as for the retrieval experiment. On D1 the volunteer
545 was contacted over the phone and interviewed about the words (D3 and D5 word list recall is
546 reported in Supplementary Material only – *Supplementary table 8*).

547

548 Testing was completed on a laptop on-site, or over the phone. The experiments were
549 programmed in the MATLAB environment (2015b or 2017a) using the Psychophysics Toolbox
550 V3 ⁷⁶. The scripts and data are available from corresponding authors upon request.

551 **Polysomnography**

552 Standard in-laboratory polysomnography, including video, was recorded during both study
553 nights using the Embla N9000 amplifier and Embla RemLogic software (Natus Medical Inc.,
554 California) at CRIC Bristol, University of Bristol, Bristol, UK. We recorded 12 scalp EEG
555 channels (F3, Fz, F4, C3, Cz, C4, M1, Pz, M2, O1, O2, and a ground electrode placed
556 approximately between Cz/P3 and C3/Pz) placed according to the 10-20 system. Eye
557 movements were detected by electro-oculogram recorded from E1 and E2 sites, and muscle tone
558 from electromyogram recorded below the chin. A 2-lead ECG was also recorded.

559 Each recording started 2.5h after dosing when lights were switched off for the night and
560 continued until the volunteer woke up. All signals were sampled at 500Hz.

561

562 **Analysis**

563 *EEG*

564 Sleep stages in 30s epochs were identified manually in accordance to standard criteria⁷⁷ by two
565 expert scorers, and a third scorer visually assessed a random 10% of ratings for quality.

566 Durations of N1, N2, N3 (i.e. slow wave sleep), REM, awake, asleep and total time in bed were
567 extracted in minutes.

568 Data was handled and analysed within the MATLAB environment using EEGLab⁷⁸ and scripts
569 written in-house (*Supplementary Figure 2*). Firstly, epochs with high amounts of noise or clear
570 artefacts were removed manually. Data was then filtered (high pass 11Hz, low pass 17Hz),
571 rectified, then smoothed using a 200ms averaging window. After which, the data were down-
572 sampled to 100Hz for computational efficiency. Spindle events were automatically marked if the
573 amplitude of the smoothed signal exceeded the 90th percentile of the data set for 0.5-3 seconds,
574 with a separation of at least 0.5 seconds to other detected spindle events.

575 **Event scoring:** Manual sleep scoring was performed in 30s epochs on REMLogic using
576 standard criteria. 10% of randomly selected scored nights were quality-controlled by a second
577 rater. Minutes in stage 1, stage 2, stage 3, REM, awake, asleep and total time in bed were
578 extracted in minutes. First and second halves of the nights were defined by the cut-off time
579 between switching lights ON and OFF. When there was an odd number of epochs, they were
580 rounded so that the first half of the night had the extra epoch.

581

582

583 **Spindle detection:** Spindle characteristics were then isolated with in-house written MATLAB
584 scripts using the EEGLab toolbox. Electrodes were re-referenced to contralateral mastoid and
585 empty and high variance epochs were removed. Following this, solely data from the Cz electrode

586 was used. First, the channel was visually inspected and epochs with high noise or clear artifacts
587 were removed manually. Data was then filtered (high pass 11Hz, low pass 17Hz) and rectified.
588 Data was then smoothed using a moving average window of 200ms. Then, data was
589 downsampled to 100Hz (from 500Hz) for computational efficiency. An event was marked as a
590 spindle if the threshold exceeded the 90th percentile for that data set (i.e. sorting data into an
591 ascending order and including top 10%) for .5 – 3 seconds and a minimum 0.5s gap between
592 spindles.

593

594 **Slow oscillations:** The slow oscillation detection process followed the same re-referencing and
595 noise removal methods used for spindle detection, without smoothing. Data from the CZ
596 electrode was filtered between 0.16Hz and 1.25Hz and z-scored. We applied a threshold of 75%;
597 if the slow oscillation amplitude surpassed this threshold for 0.5 - 5 seconds (including multiple
598 events if separated by <0.25s), it was marked as a slow oscillation event. The duration of the
599 event was determined by the closest oscillation maxima following the amplitude dropping below
600 a 60% threshold on each side.

601

602 We then compared the detected events of both types, finding cases where the maximum
603 amplitude of a spindle event occurred during a slow oscillation event. The Hilbert transform of
604 the slow oscillation was calculated to estimate the phase at which the spindle max amplitude
605 occurred. Using the time stamp of the spindle max amplitude as the centre point, we calculated
606 how spindle amplitude varied with slow oscillation phase over one cycle. 16 bins were used,
607 equally distributed in phase space, to calculate how the spindle amplitude varied with slow
608 oscillation phase for each coinciding case.

609

610 Behaviour

611 **Definition of accuracy:** Performance on the memory task was assessed using signal detection
612 theory (SDT; ^{79,80}). In short, SDT can be used to explain volunteers' response strategies for
613 discriminating between signal (targets) and noise (distractors) using the distribution of 'OLD'
614 and 'NEW' responses. As a measure of accuracy, we used d' which describes the discriminability
615 between targets and distractors by quantifying how well a volunteer detects signal from noise, or
616 targets from distractors.

617

618 **Pairwise comparisons** (placebo versus L-DOPA) were calculated using either t-tests or
619 Wilcoxon's rank tests in R 3.5.3. We also employed a Bayesian paired t-tests in JASP 0.9.2.0 ⁸¹ to
620 obtain Bayes Factors (BF) – this allows more meaningful estimates of confidence in both
621 significantly different and null results than standard t-tests. BF gives the probability of the data
622 under either hypothesis. E.g. a BF_{10} of 5 would denote that the data is 5 times more likely to have
623 been sampled from the alternative compared to the null distribution, while a BF_{01} of 5 would
624 denote that the data is 5 times less likely to have been sampled from the alternative compared to
625 the null distribution (i.e. 01 versus 10). We defined the prior (expected) distribution as a Cauchy
626 distribution with a mean of 0 and an interquartile range of .5 [$\delta \sim \text{Cauchy}(0, .5)$]. In other words,
627 we predicted that the δ lies between -.5 and .5 with a 50% confidence. We selected this one as
628 the δ s in cognitive neurosciences typically are within those bounds, and as we did not have an
629 informed prediction for the effect sizes.

630

631 All mixed modelling was performed on R 3.5.3 using Rstudio, lme4 ⁸² and lmerTest ⁸³. We
632 included the participants as random effects and the dose (mg/kg) and the memory test delay
633 (Day 1, Day 3 and Day 5), or memory strength (re-enforced versus not), depending on the
634 analysis, as fixed effects. All fixed effects were mean-centred but not scaled. We selected the

635 model using the maximum feasible fit as this has previously been shown to be the best approach
636 for confirmatory hypothesis testing⁸⁴.

637

638 **Acknowledgements**

639 First, we would like to thank each of our participants for their time. We would also like to thank
640 doctors Nicholas O'Donnolly, Lisa Knight, Hilary Archer, Elizabeth Mallam, David Evans and
641 Tom Dalton for providing clinical cover for this study, and doctors Claire Rice and Catherine
642 Pennington for their time and guidance as the steering committee. We are grateful for Alex
643 Howat, Nerea Irigoras Izagirre, and Will Mears for their substantial help in collecting the data.
644 We would like to thank Phil Boreham, cardiologist, for advising us on the safe use of
645 domperidone. We would also like to thank Join Dementia Research, Bristol Brain Centre, North
646 Bristol NHS trust, and CRICBristol staff, and our funders; the Medical Research Council,
647 BRACE Bristol and the David Telling Trust.

648 **Author contributions**

649 HKI and EJC designed Study 1. MWJ, CD, CO, and LM contributed significantly to designing
650 Study 1. Randomisation and blinding were performed by JM for Study 1. HKI, JPG and EJC
651 designed Study 2. HKI and JPG developed the verbal memory tasks. HKI, GA, JPG, WJC and
652 UB wrote all analysis scripts. Sleep scoring was performed by WJC and OR and overseen by
653 HKI, spindle and slow oscillation analyses were carried out by HKI, WJC and UB. CO and UB
654 gave further statistical guidance. All data collection was overseen by HKI, JPG and EJC. Data
655 was collected by HKI, WJC, GA, OR, JS, RW, EF, JM, CD, ARW, CMN, and JPG. Further
656 clinical cover was provided by EJC, JM and JS. HKI, EJC, WJC, JPG, CO, MWJ and UB
657 interpreted the data. HKI and EJC wrote the manuscript, all authors contributed to the editing
658 of the manuscript and approved of the final version.

659 **Competing interests statement:**

660 The authors have no competing interests.

661 **Data availability:**

662 Contact the corresponding authors for copies of the MATLAB and R scripts used in analysis,
663 the experimental standard operating procedures, MATLAB scripts for the verbal memory tasks,
664 or word list. Data will be shared in line with sponsor's requirement for availability of
665 anonymised datasets from clinical trials. The data for the control study can also be shared upon
666 request.

667

668 **Code availability:**

669 Contact the corresponding authors for copies of the MATLAB and R scripts used in analysis.

670 References

- 671 1 Tonegawa, S., Liu, X., Ramirez, S. & Redondo, R. Memory Engram Cells Have Come of Age.
672 *Neuron* **87**, 918-931, doi:10.1016/j.neuron.2015.08.002 (2015).
- 673 2 Semon, R. *Die nmemischen Empfindungen.* (Willhelm Engelmann, 1909).
- 674 3 Tononi, G. & Cirelli, C. Sleep function and synaptic homeostasis. *Sleep Med Rev* **10**, 49-62,
675 doi:10.1016/j.smrv.2005.05.002 (2006).
- 676 4 Williams, M. D. & Hollan, J. D. The Process of Retrieval from Very Long-Term-Memory.
677 *Cognitive Sci* **5**, 87-119, doi:DOI 10.1207/s15516709cog0502_1 (1981).
- 678 5 Stark, C. E. L., Okado, Y. & Loftus, E. F. Imaging the reconstruction of true and false memories
679 using sensory reactivation and the misinformation paradigms. *Learning & Memory* **17**, 485-488,
680 doi:10.1101/lm.1845710 (2010).
- 681 6 Frey, U. & Morris, R. G. M. Synaptic tagging and long-term potentiation. *Nature* **385**, 533-536,
682 doi:10.1038/385533a0 (1997).
- 683 7 Redondo, R. L. & Morris, R. G. Making memories last: the synaptic tagging and capture
684 hypothesis. *Nature reviews. Neuroscience* **12**, 17-30, doi:10.1038/nrn2963 (2011).
- 685 8 Patil, A., Murty, V. P., Dunsmoor, J. E., Phelps, E. A. & Davachi, L. Reward retroactively
686 enhances memory consolidation for related items. *Learning & Memory* **24**, 65-69,
687 doi:10.1101/lm.042978 (2017).
- 688 9 Dunsmoor, J. E., Murty, V. P., Davachi, L. & Phelps, E. A. Emotional learning selectively and
689 retroactively strengthens memories for related events. *Nature* **520**, 345-348,
690 doi:10.1038/nature14106 (2015).
- 691 10 Wang, S. H., Redondo, R. L. & Morris, R. G. M. Relevance of synaptic tagging and capture to the
692 persistence of long-term potentiation and everyday spatial memory. *Proceedings of the National*
693 *Academy of Sciences of the United States of America* **107**, 19537-19542, doi:10.1073/pnas.1008638107
694 (2010).
- 695 11 Duzskiewicz, A. J., McNamara, C. G., Takeuchi, T. & Genzel, L. Novelty and Dopaminergic
696 Modulation of Memory Persistence: A Tale of Two Systems. *Trends in Neurosciences* **42**, 102-114,
697 doi:10.1016/j.tins.2018.10.002 (2019).
- 698 12 Michon, F., Sun, J. J., Kim, C. Y., Ciliberti, D. & Kloosterman, F. Post-learning Hippocampal
699 Replay Selectively Reinforces Spatial Memory for Highly Rewarded Locations. *Current biology : CB*
700 **29**, 1436-1444.e1435, doi:10.1016/j.cub.2019.03.048 (2019).
- 701 13 Oudiette, D., Antony, J. W., Creery, J. D. & Paller, K. A. The Role of Memory Reactivation
702 during Wakefulness and Sleep in Determining Which Memories Endure. *Journal of Neuroscience* **33**,
703 6672-U6758, doi:10.1523/Jneurosci.5497-12.2013 (2013).
- 704 14 Stickgold, R. Sleep-dependent memory consolidation. *Nature* **437**, 1272-1278, doi:Doi
705 10.1038/Nature04286 (2005).
- 706 15 van de Ven, G. M., Trouche, S., McNamara, C. G., Allen, K. & Dupret, D. Hippocampal Offline
707 Reactivation Consolidates Recently Formed Cell Assembly Patterns during Sharp Wave-Ripples.
708 *Neuron* **92**, 968-974, doi:10.1016/j.neuron.2016.10.020 (2016).
- 709 16 Molle, M., Yeshenko, O., Marshall, L., Sara, S. J. & Born, J. Hippocampal sharp wave-ripples
710 linked to slow oscillations in rat slow-wave sleep. *J Neurophysiol* **96**, 62-70,
711 doi:10.1152/jn.00014.2006 (2006).
- 712 17 Yang, M. Y., Logothetis, N. K. & Eschenko, O. Occurrence of Hippocampal Ripples is
713 Associated with Activity Suppression in the Mediodorsal Thalamic Nucleus. *Journal of Neuroscience*
714 **39**, 434-444, doi:10.1523/Jneurosci.2107-18.2018 (2019).
- 715 18 Maingret, N., Girardeau, G., Todorova, R., Goutierre, M. & Zugaro, M. Hippocampo-cortical
716 coupling mediates memory consolidation during sleep. *Nat Neurosci* **19**, 959-964,
717 doi:10.1038/nn.4304 (2016).
- 718 19 Singer, A. C. & Frank, L. M. Rewarded Outcomes Enhance Reactivation of Experience in the
719 Hippocampus. *Neuron* **64**, 910-921, doi:10.1016/j.neuron.2009.11.016 (2009).
- 720 20 Ego-Stengel, V. & Wilson, M. A. Disruption of Ripple-Associated Hippocampal Activity During
721 Rest Impairs Spatial Learning in the Rat. *Hippocampus* **20**, 1-10, doi:10.1002/hipo.20707 (2010).

- 722 21 Girardeau, G., Benchenane, K., Wiener, S. I., Buzsaki, G. & Zugaro, M. B. Selective suppression
723 of hippocampal ripples impairs spatial memory. *Nat Neurosci* **12**, 1222-1223, doi:10.1038/nn.2384
724 (2009).
- 725 22 Feld, G. B. & Born, J. Neurochemical mechanisms for memory processing during sleep: basic
726 findings in humans and neuropsychiatric implications. *Neuropsychopharmacol*, doi:10.1038/s41386-
727 019-0490-9 (2019).
- 728 23 Lisman, J., Grace, A. A. & Duzel, E. A neoHebbian framework for episodic memory; role of
729 dopamine-dependent late LTP. *Trends in Neurosciences* **34**, 536-547, doi:10.1016/j.tins.2011.07.006
730 (2011).
- 731 24 Feld, G. B., Besedovsky, L., Kaida, K., Munte, T. F. & Born, J. Dopamine D2-like Receptor
732 Activation Wipes Out Preferential Consolidation of High over Low Reward Memories during
733 Human Sleep. *J Cognitive Neurosci* **26**, 2310-2320, doi:10.1162/jocn_a_00629 (2014).
- 734 25 Grogan, J. P., Bogacz, R., Tsivos, D., Whone, A. & Coulthard, E. J. Dopamine and
735 Consolidation of Episodic Memory: Timing is Everything. *J Cogn Neurosci* **27**, 2035-2050,
736 doi:10.1162/jocn_a_00840 (2015).
- 737 26 Chowdhury, R., Guitart-Masip, M., Bunzeck, N., Dolan, R. J. & Duzel, E. Dopamine Modulates
738 Episodic Memory Persistence in Old Age. *Journal of Neuroscience* **32**, 14193-14204,
739 doi:10.1523/jneurosci.1278-12.2012 (2012).
- 740 27 Franca, A. S. *et al.* D2 dopamine receptor regulation of learning, sleep and plasticity. *European*
741 *neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* **25**, 493-504,
742 doi:10.1016/j.euroneuro.2015.01.011 (2015).
- 743 28 Coulthard, E. J. *et al.* Distinct roles of dopamine and subthalamic nucleus in learning and
744 probabilistic decision making. *Brain* **135**, 3721-3734, doi:10.1093/brain/aws273 (2012).
- 745 29 Liu, D. & Dan, Y. A Motor Theory of Sleep-Wake Control: Arousal-Action Circuit. *Annual review*
746 *of neuroscience* **42**, 27-46, doi:10.1146/annurev-neuro-080317-061813 (2019).
- 747 30 Alizadeh Asfestani, M., Brechmann, V., Santiago, J., Born, J. & Feld, G. B. Consolidation of
748 reward memory during sleep does not require dopaminergic activation. *BioRxiv* (2019, bioRxiv).
- 749 31 McNamara, C. G., Tejero-Cantero, A., Trouche, S., Campo-Urriza, N. & Dupret, D.
750 Dopaminergic neurons promote hippocampal reactivation and spatial memory persistence. *Nat*
751 *Neurosci* **17**, 1658-1660, doi:10.1038/nn.3843 (2014).
- 752 32 Gomperts, S. N., Kloosterman, F. & Wilson, M. A. VTA neurons coordinate with the
753 hippocampal reactivation of spatial experience. *Elife* **4**, doi:10.7554/eLife.05360 (2015).
- 754 33 Berry, J. A., Cervantes-Sandoval, I., Nicholas, E. P. & Davis, R. L. Dopamine is required for
755 learning and forgetting in *Drosophila*. *Neuron* **74**, 530-542, doi:10.1016/j.neuron.2012.04.007
756 (2012).
- 757 34 Berry, J. A., Phan, A. & Davis, R. L. Dopamine Neurons Mediate Learning and Forgetting
758 through Bidirectional Modulation of a Memory Trace. *Cell Rep* **25**, 651-+,
759 doi:10.1016/j.celrep.2018.09.051 (2018).
- 760 35 Hsu, A., Yao, H. M., Gupta, S. & Modi, N. B. Comparison of the pharmacokinetics of an oral
761 extended-release capsule formulation of carbidopa-levodopa (IPX066) with immediate-release
762 carbidopa-levodopa (Sinemet((R))), sustained-release carbidopa-levodopa (Sinemet((R)) CR), and
763 carbidopa-levodopa-entacapone (Stalevo((R))). *Journal of clinical pharmacology* **55**, 995-1003,
764 doi:10.1002/jcph.514 (2015).
- 765 36 Birdsall, T. G. & Roberts, R. A. On the Theory of Signal Detectability - an Optimum
766 Nonsequential Observation-Decision Procedure. *Ieee Transactions on Information Theory* **11**, 195-204
767 (1965).
- 768 37 Zappia, M. *et al.* Body weight influences pharmacokinetics of levodopa in Parkinson's disease.
769 *Clin Neuropharmacol* **25**, 79-82, doi:10.1097/00002826-200203000-00004 (2002).
- 770 38 Cairney, S. A., Guttesen, A. A. V., El Marj, N. & Staresina, B. P. Memory Consolidation Is
771 Linked to Spindle-Mediated Information Processing during Sleep. *Curr Biol* **28**, 948-+,
772 doi:10.1016/j.cub.2018.01.087 (2018).
- 773 39 Antony, J. W. *et al.* Sleep Spindle Refractoriness Segregates Periods of Memory Reactivation. *Curr*
774 *Biol* **28**, 1736-1743 e1734, doi:10.1016/j.cub.2018.04.020 (2018).
- 775 40 Helfrich, R. F., Mander, B. A., Jagust, W. J., Knight, R. T. & Walker, M. P. Old Brains Come
776 Uncoupled in Sleep: Slow Wave-Spindle Synchrony, Brain Atrophy, and Forgetting. *Neuron* **97**,
777 221-230.e224, doi:10.1016/j.neuron.2017.11.020 (2018).

- 778 41 Ellis, B. W. *et al.* The St. Mary's Hospital Sleep Questionnaire: A Study of Reliability. *Sleep* **4**, 93-
779 97, doi:10.1093/sleep/4.1.93 %J Sleep (1981).
- 780 42 Parrott, A. C. & Hindmarch, I. The Leeds Sleep Evaluation Questionnaire in
781 psychopharmacological investigations - a review. *Psychopharmacology* **71**, 173-179,
782 doi:10.1007/bf00434408 (1980).
- 783 43 Berry, J. A., Cervantes-Sandoval, I., Chakraborty, M. & Davis, R. L. Sleep Facilitates Memory by
784 Blocking Dopamine Neuron-Mediated Forgetting. *Cell* **161**, 1656-1667,
785 doi:10.1016/j.cell.2015.05.027 (2015).
- 786 44 Davis, R. L. & Zhong, Y. The Biology of Forgetting-A Perspective. *Neuron* **95**, 490-503,
787 doi:10.1016/j.neuron.2017.05.039 (2017).
- 788 45 Wilhelm, I. *et al.* Sleep Selectively Enhances Memory Expected to Be of Future Relevance. *Journal*
789 *of Neuroscience* **31**, 1563-1569, doi:10.1523/Jneurosci.3575-10.2011 (2011).
- 790 46 van Rijn, E., Lucignoli, C., Izura, C. & Blagrove, M. T. Sleep-dependent memory consolidation is
791 related to perceived value of learned material. *J Sleep Res* **25**, 204-205 (2016).
- 792 47 Mölle, M., Eschenko, O., Gais, S., Sara, S. J. & Born, J. The influence of learning on sleep slow
793 oscillations and associated spindles and ripples in humans and rats. **29**, 1071-1081,
794 doi:10.1111/j.1460-9568.2009.06654.x (2009).
- 795 48 Qu, W.-M. *et al.* Essential Role of Dopamine D₂ Receptor in the Maintenance of
796 Wakefulness, But Not in Homeostatic Regulation of Sleep, in Mice. **30**, 4382-4389,
797 doi:10.1523/JNEUROSCI.4936-09.2010 %J The Journal of Neuroscience (2010).
- 798 49 Dong, H. *et al.* Dorsal Striatum Dopamine Levels Fluctuate Across the Sleep-Wake Cycle and
799 Respond to Salient Stimuli in Mice. **13**, doi:10.3389/fnins.2019.00242 (2019).
- 800 50 Eder, D. N., Zdravkovic, M. & Wildschiodtz, G. Selective alterations of the first NREM sleep
801 cycle in humans by a dopamine D1 receptor antagonist (NNC-687). *Journal of psychiatric research* **37**,
802 305-312, doi:[https://doi.org/10.1016/S0022-3956\(03\)00007-4](https://doi.org/10.1016/S0022-3956(03)00007-4) (2003).
- 803 51 Cantor, C. R. & Stern, M. B. Dopamine agonists and sleep in Parkinson's disease. *Neurology* **26**,
804 71-78 (2002).
- 805 52 MacDonald, S. W., Karlsson, S., Rieckmann, A., Nyberg, L. & Backman, L. Aging-related
806 increases in behavioral variability: relations to losses of dopamine D1 receptors. *The Journal of*
807 *neuroscience : the official journal of the Society for Neuroscience* **32**, 8186-8191,
808 doi:10.1523/JNEUROSCI.5474-11.2012 (2012).
- 809 53 Kish, S. J., Shannak, K., Rajput, A., Deck, J. H. N. & Hornykiewicz, O. Aging Produces a
810 Specific Pattern of Striatal Dopamine Loss - Implications for the Etiology of Idiopathic
811 Parkinsons-Disease. *J Neurochem* **58**, 642-648, doi:DOI 10.1111/j.1471-4159.1992.tb09766.x
812 (1992).
- 813 54 Carlsson, A. *et al.* Biogenic amines in human brain in normal aging, senile dementia, and chronic
814 alcoholism. *Adv Biochem Psychopharmacol* **23**, 295-304 (1980).
- 815 55 Latreille, V. *et al.* Sleep spindles in Parkinson's disease may predict the development of dementia.
816 *Neurobiology of aging* **36**, 1083-1090, doi:<https://doi.org/10.1016/j.neurobiolaging.2014.09.009>
817 (2015).
- 818 56 Contreras, D., Destexhe, A., Sejnowski, T. J. & Steriade, M. Spatiotemporal patterns of spindle
819 oscillations in cortex and thalamus. *The Journal of neuroscience : the official journal of the Society for*
820 *Neuroscience* **17**, 1179-1196 (1997).
- 821 57 Nir, Y. *et al.* Regional slow waves and spindles in human sleep. *Neuron* **70**, 153-169,
822 doi:10.1016/j.neuron.2011.02.043 (2011).
- 823 58 Cox, R., Schapiro, A. C., Manoach, D. S. & Stickgold, R. Individual Differences in Frequency and
824 Topography of Slow and Fast Sleep Spindles. *Front Hum Neurosci* **11**, 433,
825 doi:10.3389/fnhum.2017.00433 (2017).
- 826 59 Blaskovich, B., Szollosi, A., Gombos, F., Racsmany, M. & Simor, P. The Benefit of Directed
827 Forgetting Persists After a Daytime Nap: The Role of Spindles and Rapid Eye Movement Sleep
828 in the Consolidation of Relevant Memories. *Sleep* **40**, doi:10.1093/sleep/zsw076 (2017).
- 829 60 Heib, D. P. J. *et al.* Oscillatory Theta Activity during Memory Formation and Its Impact on
830 Overnight Consolidation: A Missing Link? *J Cognitive Neurosci* **27**, 1648-1658,
831 doi:10.1162/jocn_a_00804 (2015).
- 832 61 Staresina, B. P. *et al.* Hierarchical nesting of slow oscillations, spindles and ripples in the human
833 hippocampus during sleep. *Nat Neurosci* **18**, 1679-1686, doi:10.1038/nn.4119 (2015).

- 834 62 Frey, U. & Morris, R. G. M. Weak before strong: Dissociating synaptic tagging and plasticity
835 factor accounts of late-LTP. *Eur J Neurosci* **10**, 20-20 (1998).
- 836 63 Clopath, C. Synaptic consolidation: an approach to long-term learning. *Cogn Neurodynamics* **6**, 251-
837 257, doi:10.1007/s11571-011-9177-6 (2012).
- 838 64 Sajikumar, S. & Frey, J. U. Late-associativity, synaptic tagging, and the role of dopamine during
839 LTP and LTD. *Neurobiol Learn Mem* **82**, 12-25, doi:10.1016/j.nlm.2004.03.003 (2004).
- 840 65 O'Donnell, C. & Sejnowski, T. J. Selective Memory Generalization by Spatial Patterning of
841 Protein Synthesis. *Neuron* **82**, 398-412, doi:10.1016/j.neuron.2014.02.028 (2014).
- 842 66 Rauchs, G. *et al.* Sleep Contributes to the Strengthening of Some Memories Over Others,
843 Depending on Hippocampal Activity at Learning. *Journal of Neuroscience* **31**, 2563-2568,
844 doi:10.1523/Jneurosci.3972-10.2011 (2011).
- 845 67 Morcom, A. M. *et al.* Memory Encoding and Dopamine in the Aging Brain: A
846 Psychopharmacological Neuroimaging Study. *Cerebral Cortex* **20**, 743-757,
847 doi:10.1093/cercor/bhp139 (2010).
- 848 68 Nicolas, A., Petit, D., Rompre, S. & Montplaisir, J. Sleep spindle characteristics in healthy
849 subjects of different age groups. *Clinical neurophysiology : official journal of the International Federation of*
850 *Clinical Neurophysiology* **112**, 521-527 (2001).
- 851 69 Crowley, K., Trinder, J., Kim, Y., Carrington, M. & Colrain, I. M. The effects of normal aging on
852 sleep spindle and K-complex production. *Clinical neurophysiology : official journal of the International*
853 *Federation of Clinical Neurophysiology* **113**, 1615-1622 (2002).
- 854 70 Walker, M. P. The Role of Slow Wave Sleep in Memory Processing. *Journal of clinical sleep medicine :*
855 *JCSM : official publication of the American Academy of Sleep Medicine* **5**, S20-S26 (2009).
- 856 71 Xie, L. *et al.* Sleep Drives Metabolite Clearance from the Adult Brain. *Science* **342**, 373-377,
857 doi:10.1126/science.1241224 (2013).
- 858 72 Ju, Y.-E. S. *et al.* Slow wave sleep disruption increases cerebrospinal fluid amyloid- β levels. *Brain*
859 **140**, 2104-2111, doi:10.1093/brain/awx148 (2017).
- 860 73 Diederich, N. J., Paolini, V. & Vaillant, M. Slow wave sleep and dopaminergic treatment in
861 Parkinson's disease: a polysomnographic study. *Acta neurologica Scandinavica* **120**, 308-313,
862 doi:10.1111/j.1600-0404.2009.01167.x (2009).
- 863 74 Joy, S. P. *et al.* Serial macro-architectural alterations with levodopa in Parkinson's disease:
864 Polysomnography (PSG)-based analysis. *Annals of Indian Academy of Neurology* **18**, 309-313,
865 doi:10.4103/0972-2327.160102 (2015).
- 866 75 Wailke, S., Herzog, J., Witt, K., Deuschl, G. & Volkmann, J. Effect of controlled-release
867 levodopa on the microstructure of sleep in Parkinson's disease. *European journal of neurology* **18**,
868 590-596, doi:10.1111/j.1468-1331.2010.03213.x (2011).
- 869 76 Kleiner, M., Brainard, D. & Pelli, D. What's new in Psychtoolbox-3? *Perception* **36**, 14-14 (2007).
- 870 77 Berry, R. B. *et al.* AASM Scoring Manual Updates for 2017 (Version 2.4). *J Clin Sleep Med* **13**, 665-
871 666, doi:10.5664/jcsm.6576 (2017).
- 872 78 Delorme, A. & Makeig, S. EEGLAB: an open source toolbox for analysis of single-trial EEG
873 dynamics including independent component analysis. *J Neurosci Meth* **134**, 9-21,
874 doi:10.1016/j.jneumeth.2003.10.009 (2004).
- 875 79 Treisman, M. The Effect of One Stimulus on the Threshold for Another - an Application of
876 Signal Detectability Theory. *Brit J Statist Psych* **17**, 15-35 (1964).
- 877 80 Birdsall, T. G. & Roberts, R. A. On the Theory of Signal Detectability - an Optimum
878 Nonsequential Observation-Decision Procedure. *Ieee T Inform Theory* **11**, 195-204, doi:Doi
879 10.1109/Tit.1965.1053740 (1965).
- 880 81 JASP v. Version 0.9 (2018).
- 881 82 Package 'lme4' v. 1.1-21 (2019).
- 882 83 lmerTest: Tests in Linear Mixed Effects Models v. 3.1-0 (2019).
- 883 84 Barr, D. J., Levy, R., Scheepers, C. & Tily, H. J. Random effects structure for confirmatory
884 hypothesis testing: Keep it maximal. *J Mem Lang* **68**, 255-278, doi:10.1016/j.jml.2012.11.001
885 (2013).

886